Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds
The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.
1. An anticancer chalcone compound represented by:
wherein, R 2 and R 3 are independently hydrogen or hydroxyl, wherein at least one of R 2 and R 3 is hydroxyl, and R 4 is (C 1 -C 5 ) alkyl or (C 6 -C 10 ) aryl optionally substituted with one or more substituents selected from the group consisting of halogen, nitro and (C 1 -C 5 ) alkyl, or a pharmaceutically acceptable salt thereof.
2. An anticancer chalcone compound selected from the group consisting of:
4′-(p-toluenesulfonate)-4-hydroxychalcone;
4′-(p-fluorobenzenesulfonate)-4-hydroxychalcone;
4′-(m-fluorobenzenesulfonate)-4-hydroxychalcone;
4′-(p-nitrobenzenesulfonate)-4-hydroxychalcone;
4′-(p-aminobenzenesulfonate)-4-hydroxychalcone;
4′-(benzenesulfonate)-4-hydroxychalcone;
4′-(methanesulfonate)-4-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-4-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-3-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2-hydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-4-hydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-3-hydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-2-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-3,4-dihydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2,3-dihydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2,4-dihydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2,5-dihydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-3,4-dihydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-2,3-dihydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-2,4-dihydroxychalcone; and
4′-(m-hydroxybenzenesulfonate)-2,5-dihydroxychalcone.
3. A method for inhibiting TM4SF5 comprising administering to a subject in need of treatment for cancer a therapeutically effective amount of a chalcone compound of claim 1 .
4. The method of claim 3 , wherein the chalcone compound comprises:
4′-(p-toluenesulfonate)-4-hydroxychalcone;
4′-(p-fluorobenzenesulfonate)-4-hydroxychalcone;
4′-(m-fluorobenzenesulfonate)-4-hydroxychalcone;
4′-(p-nitrobenzenesulfonate)-4-hydroxychalcone;
4′-(p-aminobenzenesulfonate)-4-hydroxychalcone;
4′-(benzenesulfonate)-4-hydroxychalcone;
4′-(methanesulfonate)-4-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-4-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-3-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2-hydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-4-hydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-3-hydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-2-hydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-3,4-dihydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2,3-dihydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2,4-dihydroxychalcone;
4′-(p-hydroxybenzenesulfonate)-2,5-dihydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-3,4-dihydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-2,3-dihydroxychalcone;
4′-(m-hydroxybenzenesulfonate)-2,4-dihydroxychalcone; and
4′-(m-hydroxybenzenesulfonate)-2,5-dihydroxychalcone.